Anti-ASPH monoclonal antibody Made to order

Name: Anti-ASPH monoclonal antibody
SKU: DCABH-10644
Rating: 5 (1 reviews)

Rabbit anti-Human ASPH monoclonal antibody for WB, ELISA

Write a review

COA

SDS

Datasheet

Summary

Specifications

Antibody Isotype

IgG

Species Reactivity

Human

Immunogen

A synthetic peptide of human ASPH is used for rabbit immunization.

Conjugate

Unconjugated

Target

Alternative Names

ASPH; aspartate beta-hydroxylase; aspartyl/asparaginyl beta-hydroxylase; BAH; CASQ2BP1; HAAH; humbug; JCTN; junctate; junctin; A beta H-J-J; cardiac junctin; ASP beta-hydroxylase; peptide-aspartate beta-dioxygenase; aspartyl/asparaginyl-beta-hydroxylase;

Entrez Gene ID

444

UniProt ID

Q12797

Product Background

Antigen Description

This gene is thought to play an important role in calcium homeostasis. The gene is expressed from two promoters and undergoes extensive alternative splicing. The encoded set of proteins share varying amounts of overlap near their N-termini but have substantial variations in their C-terminal domains resulting in distinct functional properties. The longest isoforms (a and f) include a C-terminal Aspartyl/Asparaginyl beta-hydroxylase domain that hydroxylates aspartic acid or asparagine residues in the epidermal growth factor (EGF)-like domains of some proteins, including protein C, coagulation factors VII, IX, and X, and the complement factors C1R and C1S. Other isoforms differ primarily in the C-terminal sequence and lack the hydroxylase domain, and some have been localized to the endoplasmic and sarcoplasmic reticulum. Some of these isoforms are found in complexes with calsequestrin, triadin, and the ryanodine receptor, and have been shown to regulate calcium release from the sarcoplasmic reticulum. Some isoforms have been implicated in metastasis.

Citations

Have you cited DCABH-10644 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Q & A

Ask a Question

Q: What are the applicable experiments for the Anti-ASPH monoclonal antibody?

A: The Anti-ASPH monoclonal antibody can be utilized in WB, ELISA.

Customer Reviews

References

Identification of environmental and genetic factors that influence warfarin time in therapeutic range

GENETICS AND MOLECULAR BIOLOGY

Authors: Botton, Mariana R.; Viola, Patricia P.; Meireles, Mariana R.; Bruxel, Estela M.; Zuchinali, Priccila; Bandinelli, Eliane; Rohde, Luis E.; Leiria, Tiago L. L.; Salamoni, Joyce Y. Y.; Garbin, Arthur P.; Hutz, Mara H.

Abstract

Warfarin is an oral anticoagulant prescribed to prevent and treat thromboembolic disorders. It has a narrow therapeutic window and must have its effect controlled. Prothrombin test, expressed in INR value, is used for dose management. Time in therapeutic range (TTR) is an important outcome of quality control of anticoagulation therapy and is influenced by several factors. The aim of this study was to identify genetic, demographic, and clinical factors that can potentially influence TTR. In total, 422 patients using warfarin were investigated. Glibenclamide co-medication and presence of CYP2C9*2 and/or *3 alleles were associated with higher TTR, while amiodarone, acetaminophen and verapamil co-medication were associated with lower TTR. Our data suggest that TTR is influenced by co-medication and genetic factors. Thus, individuals in use of glibenclamide may need a more careful monitoring and genetic testing (CYP2C9*2 and/or *3 alleles) may improve the anticoagulation management. In addition, in order to reach and maintain the INR in the target for a longer period, it is better to discuss dose adjustment in office instead of by telephone assessment. Other studies are needed to confirm these results and to find more variables that could contribute to this important parameter.

Synthesis of arsenic(V) octaethylporphyrins and X-ray crystal structure of [(OEP)As(Me)(OH)]ClO4

ORGANOMETALLICS

Authors: Satoh, W; Nadano, R; Yamamoto, G; Yamamoto, Y; Akiba, K

Abstract

[(OEP)As(OH)(2)]ClO4 (4-ClO4) and [(OEP)As(Ph)(OK)]ClO4 (12-ClO4) are synthesized in good yields by oxidative conversion of(OEP)AsCl (2) and (OEP)AsPh (10), respectively, with pyridinium tribromide followed by hydrolysis and counteranion exchange. 4-Cl is converted to [(OEP)As(R)(OH)]ClO4 (6-ClO4, R = Me; 8-ClO4, R = Et) and [(OEP)As(R)(2)]X (7-ClO4, R = Me; 9-PF6, R = Et) by the reaction with (COBr)(2) followed by treatment with trialkylaluminum (alkyl = Me, Et) and counteranion exchange. The reaction of 6-Cl with PCl3 gives the corresponding chloride [(OEP)As(Me)(Cl)]Cl (13-Cl), from which [(OEP)As(Me)(OR)]ClO4 (14-ClO4, R = Me; 15-ClO4, R = Et; 16-ClO4, R = i-Pr), [(OEP)As(Nle)(NH-n-Bu)]ClO4 (17-ClO4>, [(OEP)As(Me)(NH-p-CH3C6H4)]ClO4 (18-ClO4), and [(OEP)As(Me)(Et)]ClO4 (19-ClO4) are synthesized. These compounds are stable toward air and moisture. The OH protons of [(OEP)As(R)(OH)]Cl (6-Cl, R = Me; 8-Cl, R = Et, 12-Cl, R = Ph) are acidic enough to generate [((OEP)As(R)=O)] (20, R = Me; 21, R = Et, 22, R = Ph) by treatment of a solution of 6-Cl, 8-Cl, and 12-Cl with 1,8-diazabicyclo[5,4.0]undec-7-ene (DBU). 6-Cl, 8-Cl, and 12-Cl are regenerated by treating a solution of 20, 21, and 22 with dilute HCl. The first characterization of an arsenic porphyrin 6-ClO4, by X-ray crystallographic analysis is presented.